Information Provided By:
Fly News Breaks for May 8, 2015
VRTX
May 8, 2015 | 10:10 EDT
Piper Jaffray said the briefing documents posted for next Tuesday's advisory committee meeting on Vertex's Orkambi combo drug did not raise any new or surprise safety concerns and that the efficacy concerns raised do not "hold much water" when compared to the unmet clinic benefit of the drug. The firm said it remains confident in a positive panel vote and approval of the drug by the May 5 PDUFA date and reiterate kits Overweight rating and $146 price target on Vertex shares.
News For VRTX From the Last 2 Days
There are no results for your query VRTX